drugset / Trial / NCT02417298

Ketamine Infusion for Acute Sickle Cell Crisis in the Emergency Department

NCT02417298 ↗

Terminated 12 enrolled Billy Sin
RandomizedSingle-groupQuadruple-blindTreatment

Summary

Pain associated with sickle cell disease is a common emergency department visit. It is also frequently associated with a high emergency department recidivism rate for pain control and admissions to the hospital. Opiates are considered the first line therapy for acute flares and to manage chronic pain. This often times leads to a stigma of being "opiate seekers" or "frequent fliers". With this study, we wish to explore whether adding ketamine to standard acute opiate therapy (morphine or dilaudid) will decrease subsequent repeat doses of opiates while improving the patient's perception of pain. In addition, we will be exploring whether ketamine as an adjuvant therapy can help reduce hospital admissions for the management of acute sickle cell crisis pain.

Timeline

Start
2015-11
Primary completion
2018-04-01
Completion
2018-05-01

Outcome

Outcome not reported

Stopped: “Feasibility”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ketamine Small molecule 0.1 mg/kg Intravenous

Indications